- Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer
-
Kalachand RD, O’Riain C, Toomey S, Carr A, Timms KM, O’Toole S, Madden S, Bates M, O’Leary JJ, Gleeson N, O’Donnell D, Grogan L, Breathnach O, Farrelly A, Stordal B, Hennessy BT
- KMID: 2506507
- Obstet Gynecol Sci.
- 2020 Sep;63(5):643-654.
- doi: 10.5468/ogs.20033
Objective The therapeutic benefits of poly(ADP-ribose) polymerase inhibitors highlight the need to evaluate BRCA1/2 defects in tubal/ovarian cancer (OC). We sought to determine the pattern and disease characteristics associated with... -
- CITED
-
- Close
- SHARE
-
- Close
